Researchers find how a SARS-CoV-2 virus protein damages the heart
In their study, the researchers from the University of Maryland School of Medicine found that the Nsp6 SARS-CoV-2 protein causes heart damage.
List view / Grid view
In their study, the researchers from the University of Maryland School of Medicine found that the Nsp6 SARS-CoV-2 protein causes heart damage.
Researchers have found that beer hop compounds can inhibit the clumping of proteins associated with Alzheimer's disease.
A UNIGE team reveals that a drug used against herpes can fight a bacterium that is resistant to most antibiotics by weakening its defence mechanisms.
US scientists have found strong evidence for testing VCU-manufactured drugs in liver cancer.
The College of American Pathologists has given accreditation to Altasciences’ clinical site in Los Angeles, California.
Tune in to this podcast to hear experts discuss 3D cell models, organoids and the automation of complex cell assays.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
27 October 2022 | By SPT Labtech
In this webinar, you will get a practical walk-through of how to make consistent transfers from a deep well block to a crystal screening plate using an automated pipetting system and examine best practice setting up sitting-drop vapour diffusion crystallisation.
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.